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The intestinal epithelium represents a critical barrier protecting the host against diverse luminal noxious agents, as well as
preventing the uncontrolled uptake of bacteria that could activate an immune response in a susceptible host. The epithelial
monolayer that constitutes this barrier is regulated by a meshwork of proteins that orchestrate complex biological function such as
permeability, transepithelial electrical resistance, and movement of various macromolecules. Because of its key role in maintaining
host homeostasis, factors regulating barrier function have attracted sustained attention from the research community. This paper
will address the role of bacteria, bacterial-derived metabolism, and the interplay of dietary factors in controlling intestinal barrier
function.
1. Introduction
The gastrointestinal tract (GI) from the mouth to the rectum
is lined by a single layer of cells that provides both phys-
ical protection from the potentially irritant and antigenic
substances present in the luminal compartment and also
performs essential biological functions such as absorption,
secretion, and transport of various nutrients and water. In the
lower GI tract, the intestine is divided into two distinctive
anatomical sections: the small and large intestines. Impor-
tantly, the intestinal epithelium is constantly in a self-renewal
state where proliferative stem-cell-containing crypts generate
various specific cell lineages, namely, enterocytes, enteroen-
docrine cells, Paneth cells, and goblet cells. Biological events
regulating intestinal epithelial cell proliferation, differentia-
tion, migration, and survival are all implicated in the control
of intestinal barrier function. Although, the distribution and
ratio of these cells along the GI tract vary, collectively they
protect the host against luminal contents; this single layer of
cells forms a tight barrier preventing access of noxious sub-
stances to the underlining abundant immune cells. Moreover,
the intestine is home to an estimated 1014 bacteria, termed the
gutmicrobiota, which surpasses by a factor of 10 the estimated
1013 human cells. It is essential for host homeostasis to prevent
an unregulated uptake/translocation of this microbiome, and
the maintenance of an intact epithelial barrier plays a pivotal
role in this function.There is significant interest in identifying
factors and conditions influencing intestinal barrier function
as these could have a profound impact on pathologies such as
inflammatory bowel diseases (IBD) and colorectal cancer.
The intestinal epithelium evolved in a unique environ-
ment where dietary metabolites, bacteria, and bacterial-
derivedmetabolites are omnipresent.This environment likely
provides a synergistic interaction between this tripartite that
potentially influences each component. For example, the
epithelium impacts microbial communities by producing
various mucin products and antimicrobial factors that limit
bacterial colonization and adherence. In addition, bacteria
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provide, as byproducts of their metabolism, various com-
pounds (essential vitamins, antioxidants, short-chain fatty
acid (SCFA), ect.) that impact host homeostasis [1, 2]. Finally,
composition of dietary intake can also have significant
impact on both the gut epithelial barrier and the bacterial
communities [3–5].
In this paper we focus on providing an overview of the
latest emerging research that attempts to unify elements of
these three fields: intestinal epithelial barrier, microbiome,
and dietary intake—specifically, how these interact and
modulate one another. We will discuss emerging studies
into the molecular effects of short-chain fatty acids, their
production by bacteria through intake of prebiotic fiber and
resistant starches, and emerging details on probiotics and
their mechanisms of action.
2. The Intestinal Barrier
The mucosa surrounding the lumen forms a barrier to the
microbiome and is comprised of a single layer of epithelial
cells. An intact barrier is a prerequisite for normal health,
and rapid resealing after injury is essential for prevention
of disease [6, 7]. The epithelial barrier has the unenviable
task of confining themicrobiome and any potentially harmful
substances to the lumen while regulating the flow of solutes,
nutrients, and ions into the underlying mucosa [8, 9]. Trans-
fer through an intact epithelium occurs by two routes: (1)
across the apical plasma membrane via specialized channels
(transcellular) and (2) through the paracellular space between
epithelial cells via pores created by the paracellular junc-
tion proteins. The intercellular junctions consist of Zonula
Occludens (tight junctions (TJs)) and Zonula Adherens (AJs)
collectively known as the apical junction complex (AJC),
gap junctions, and Desmosomes [10]. AJC formation confers
cell polarity and selective barrier permeability. Maintaining
barrier homeostasis requires the coordination of (1) the TJ
proteins, (2) the actin cytoskeleton, (3) endocytosis, and
(4) intracellular signaling pathways. In addition to these
well-orchestrated processes, the commensal bacteria play an
active role in maintaining host barrier homeostasis, likely by
regulating cell renewal, promoting wound healing repair, and
reorganizing the TJs.
Of all the transmembrane proteins (claudins, occludin,
MarvelD3, JAM-A, tricellulin and lipolysis-stimulated lipo-
protein receptor, LSR) [11–13], claudins determine the selec-
tive permeability of the barrier. This is achieved by different
patterns of charged amino acids in the extracellular loops
of individual claudin proteins, which interact to generate
different sized pores through which solute transfer occurs
[14–17].
While TJ stability is required for maintenance of barrier
integrity, TJ formation has to be dynamic to accommodate
intestinal epithelial cell turnover that occurs every 4-5 days
[18]. To this end, TJ proteins are continuously internalized
and recycled back to the plasma membrane via endocytosis.
Under normal physiological conditions, the macroscopic
renewal of TJs involves continuous strand breakage and refor-
mation involving clathrin-mediated endocytosis [19, 20]. In
contrast, claudins are recycled via amechanism similar to that
used for gap junction internalization, where TJ membranes
are endocytosed together into one of the adjoining cells [21].
During internalization, the claudins separate from other TJ
proteins and generate claudin-enriched vesicles, which have
the potential to regulate the claudin composition of TJs.
TJ turnover and claudin expression can also be mod-
ulated by cytokines as a plausible mechanism for neutro-
phil migration across epithelial barriers [22]. In particular,
TNF increased paracellular permeability in vitro by claudin
downregulation [23]. Furthermore, cytokine-induced inter-
nalization of TJ proteins can be blocked in vitro using
inhibitors of clathrin-mediated endocytosis [20]. TJ recycling
can also be hijacked by pathogenic bacteria (e.g., enteropatho-
genic E. coli, H. pylori, and C. difficile) [24]. Bacterial-
induced inflammation also increases claudin internalization
and increases permeability [25, 26]. Macropinocytosis is
another route in which TJ proteins can be internalized [27]
and colocalize with markers of early and recycling endo-
somes. These data suggest a plausible mechanism for rapid
redistribution of protein back to the TJ, sealing the epithelial
barrier after an inflammatory insult has subsided [28].
Physiological regulation of barrier homeostasis relies on
tightly controlled signal transduction pathways that converge
on the cytoplasmic TJ proteins [29–36]. The cytoplasmic
TJ proteins (ZO-1, -2, and -3; cingulin; and afadin) link
the transmembrane proteins to the actin cytoskeleton and
also act as scaffolds for major signaling complexes [29, 30,
37–39]. Phosphorylating components of the cytoskeleton,
namely, myosin light chain (MLC) via myosin light chain
kinase (MLCK) or Rho-associated kinase (ROCK), cause it
to contract, which separates the TJ and increases paracel-
lular permeability [28, 40–42]. In addition to the physical
separation of the TJ, ROCK compromises barrier integrity by
increasing endocytosis of TJ proteins [28]. Current opinion
suggests regulation of TJs is a delicate balance between
interacting networks incorporating protein kinase C (PKC),
protein kinase A (PKA), mitogen-activated protein kinases
(MAPK), and phosphoinositide 3-kinase (PI3-K) [42–45].
Though regulation of epithelial cell-cell junctions is an
important factor for maintenance of homeostasis, a func-
tional epithelium also requires regulation of IEC survival
[46]. Differentiated cells traveling up from the crypt base
(enterocytes, enteroendocrine cells, and goblet cells) to the
villi are thought to die from anchorage-independent death
(anoikis). However, recent findings show that at least a
part of these sloughed-off cells can survive for a time after
being evicted, giving credence to the hypothesis that these
cells are sloughed off by simple lack of space due to cell
overcrowding [47]. Additionally, apoptosis was believed to
be the main regulator of intestinal epithelial cell numbers
[48], given the strong in vivo staining patterns of caspase-3
in the gastrointestinal epithelium [49] and studies correlating
caspase-3 and apoptosis in IECs shed from the intestinal
monolayer [50, 51]. Mounting evidence supports, however,
that the recently described necroptosis, or highly regulated
programmed necrosis, is another active pathway that appears
to regulate the intestinal epithelium homeostasis in response
to different stimuli, including TNF-𝛼 which can also activate
the apoptotic pathway [52–54]. Though born with seemingly
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normal epithelium, mice with the IEC-specific deletion of
either caspase-8 or of Fas-associated protein with death
domain (FADD), two proteins involved in cell death, quickly
developed postnatal spontaneous phenotypes. IEC-specific
deletion of caspase-8, for example, resulted in development
of spontaneous ileitis with an 80% penetrance and was found
to be responsible for TNF-𝛼-induced necroptosis [52]. Mice
with IEC-specific deletion of FADD showed reduced weight,
diarrhea, and the development of spontaneous colitis, and
the IECs of which were shown to have undergone necrotic
cell death not apoptosis [55]. These findings indicate that
numerous pathways regulate various aspects of IEC survival,
a critical biological process for intestinal barrier function.
It is clear that alterations in normal signal transduc-
tion pathways that impact barrier homeostasis (prolifer-
ation/apoptosis/necroptosis) result in unregulated passage
of luminal bacteria across the epithelium and subsequent
aberrant activation of themucosal immune system, leading to
inflammation [40, 56, 57]. Increasing evidence also indicates
that barrier function and its complex regulatory network are
influenced by the microbiota and dietary components, both
directly through endogenously producedmicrobial products,
as well as indirectly through the metabolites in the host diet.
3. Microbial Products and the Intestinal
Epithelial Barrier
A wide array of pattern recognition receptors (PRR) are
implicated in the sensing/detection of various microbial
structures such as membrane components, nucleic acids, and
motility apparatuses [58].
Toll-like receptors (TLRs) andNod-like receptors (NLRs)
are probably the most studied PRRs in the intestine, and
their contribution to barrier function was investigated using
various models of intestinal injury [59–61]. For example,
TLR2 signaling through PKC is essential to enhance ZO-
1-associated barrier function in intestinal epithelial cells
following dextran-sulfate-sodium (DSS) exposure [62]. In
addition, TLR4 and the signaling protein MyD88 have been
shown to play a beneficial role in wound healing responses
and restoration of barrier integrity in DSS-induced acute
injury [63]. In addition, deletion of signaling molecules
downstream of TLRs such as nuclear factor kappa B (NF-
𝜅B) essential modulator (NEMO), the NF-𝜅B transcriptional
subunit RelA, TGF-𝛽-activated kinase, and other I𝜅B kinases
within the intestinal epithelium results in increased suscepti-
bility to colitis [64–67].
Although these findings highlight the important role of
microbial structures in regulating barrier function, another
layer of complexity is the relationship between the bioactive
potential of the microbiota and the intestinal barrier. Indeed,
the identification of specificmicroorganisms producing com-
pounds involved in the modulation of intestinal barrier
function has gained tremendous attention.
Microorganisms and their associated genome (∼3 × 106
genes) are likely to produce compounds that shape host
response. Indeed, the beneficial effects of lactic-acid produc-
ing organisms in fermentedmilk products on healthwere first
proposed at the beginning of the 20th century byMetchnikoff
[68]. Fermented milk products (FM) are representative of
a group of natural compounds and microorganisms known
as probiotics, which are defined as food supplements that
are intended to improve health [69]. Probiotics have gained
enormous interest in recent years as ameans to helpmaintain
intestinal homeostasis and/or alleviate specificGI pathologies
[70–75]. In fact some strains of probioticmicrobes can reduce
gut permeability through direct effects on intestinal epithelial
cells and reduce inflammation [5, 76–78]. Probiotics can
mediate their beneficial activity through several mechanisms
including (a) competitive exclusion of bacterial adherence
and/or translocation; (b) release of bacteriocidin and lactic
acid, which can inhibit the growth of pathogens; (c) produc-
tion of butyric acid; (d) antioxidative effects; (e) enhancement
of barrier function; (f) modulation of immune cell response;
and (g) inhibition of NF-𝜅B activation [79–87]. We will
discuss several of the most prominently emerging probiotic
foods and microorganisms that impact the intestinal barrier.
Although probiotics have a relatively safe track record
in humans, some studies have raised concerns about intro-
ducing billions of bacteria into a host [88, 89]. In an effort
to circumvent this potential health hazard, attention has
been directed on identifying probiotic-derived beneficial
molecules that can be used in lieu of whole, live microor-
ganisms. A recent report has shown that a recombinant
40 kDa soluble protein derived from Lactobacillus rhamnosus
GG (LGG) is able to reproduce the antiapoptotic effect
of the bacterium in vitro, a process mediated through an
EGFR-dependent mechanism [73]. Importantly, the delivery
of LGGp40 to the colon in vivo using a novel pectin/zein
hydrogel bead system, is able to ameliorate DSS-induced
intestinal injury as well as oxazolone-induced Th2-driven
colitis [73]. Administration of supernatant from LGG cul-
tures (LGGsup), prior to oral gavagewith ethanol, significantly
ameliorated the multiple alcohol-induced damaging effects
to the ileal epithelium. The protective effect of LGGsup on
ethanol-induced increased barrier permeability was multi-
factorial. It reversed the ethanol-mediated downregulation
of TJ proteins ZO-1, claudin, and occluding, among others,
and the mucosal protective proteins ITF, CRAMP, and P-gp
mRNAs. In addition, LGGsup reversed the alcohol-induced
decrease of Hif-2𝛼mRNA and protein levels. As the mucosal
protective proteins ITF, CRAMP, and P-gp are under Hif
transactivational control, this suggests that maintenance of
this transcription factor may play a strong role in LGGsup-
mediated effects.
Another lactobacillus with therapeutic potential is L.
brevis SBC8803, which, unlike LGG, reportedly has benefi-
cial effects when administered as a heat-killed, freeze-dried
purification of monocultures. In a recent report, heat-killed
L. brevis was able to dose-dependently induce heat shock
proteins (Hsp) 25, 27, and 70 in vitro using the colonic
cell line, Caco-2, Hsps, being important stress-induced pro-
teins involved in the protection of the colonic epithelium
against bacterial-induced injury [90–92]. Daily transanal
administration of 0.1% freeze-dried L. brevis culture in saline
decreased DSS-induced intestinal inflammation, improved
survival, and decreased expression of TNF-𝛼, IL-12, and IL-1𝛽
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[72], highlighting the importance of identifying the differing
mechanisms of action of different Lactobacilli.
Lactobacillus plantarum (Lp) is a probiotic that has been
the subject of numerous studies on the human GI system
since the early 1990s [93]. This bacterium, which has been
isolated from both healthy human intestine and the more
potent strain isolated from sourdough (isolate 299V, aka
DSM 9843), appears to have many beneficial effects in both
animal models [94, 95] and human studies [96, 97]. Recent
studies have further supported the potential of Lp in treating
intestinal disorders. A small, 40-patient randomized, double-
blind clinical trial showed that Lp resolved abdominal pain
in all IBS patients compared to the control group and pro-
vided significant bowel movement regularity to constipated
patients [96]. A recent, large scale follow-up clinical trial
was performed using similar parameters and metrics and
demonstrated beneficial effects [98]. While these and other
studies focused on the ability of Lp to ameliorate overall
disease either in animal models or in clinical trials, the
underlying molecular pathways have just recently begun to
be elucidated. Using a rat model of obstructive jaundice,
analysis of the terminal ileum has provided a fairly thorough
molecular characterization of the effects of a twice-daily
oral gavage using Lp. Specifically, the authors found that
Lp lowered obstructive jaundice-mediated intestinal epithe-
lial cell (IEC) apoptosis and importantly increased mRNA
expression of TJ proteins claudin-1 and -4, occludin, and ZO-
1, in addition to PKC. Markedly increased JAM-A and PKC
protein levels were also reported [99]. This increase in TJ
proteins is consistent with an earlier study, which revealed
intake of Lp maintains the intestinal barrier integrity in rats
exposed to E. coli by inhibiting the E. coli-induced increase
in barrier permeability [94]. Given the above-mentioned
studies, one can assume this latter effect is likely through the
increase of TJ proteins. Notably, Lp has also been suggested to
release factors that significantly inhibit pathogenic bacterial
adhesion to the mucosa [100]. Hence, the beneficial effect
of Lp appears to center on upregulation of TJ proteins to
strengthen the barrier, though it may also work to keep
pathogens from adhering to the epithelium and invading the
host. In addition, the beneficial effects of bacteria could be
mediated through production of metabolites such as SCFA
generated from the host diet.
4. Bacteria-Produced SCFA and the Intestinal
Epithelium Barrier
The anaerobic environment of the intestine allows certain
gut microbes to harness nutrients through fermentation of
nutrients passing through the lumen, resulting in the gener-
ation of a large array of metabolites. Among the metabolites
produced by this process are essential vitamins such a vitamin
K and most of the water-soluble B vitamins such as biotin,
cobalamin, and riboflavin [101], which are then absorbed
by the host [102]. Also among these metabolites are the
SCFA, such as propionate, acetate, and butyrate derived
from dietary fiber, fermentable carbohydrates, and resistant
starches, which are not broken down in the upper digestive
tract [103]. Fermentation of dietary fiber is important to
intestinal homeostasis as this process induces upper gastroin-
testinal motility [104] and the satiety hormones glucagon-
like peptide-1 (GLP-1) and peptide YY (PYY) [105–108]. In
addition, not only do these SCFAs show therapeutic potential
in treatment of patientswith IBD [109, 110], but these bacterial
derivatives also appear to further improve colonic health [111].
Interestingly, patients with ulcerative colitis (UC) appear
to have impaired butyrate metabolism [112]. As such, the
molecular mechanisms of action of these SCFA have become
a subject of increasing investigation.
The presence of SCFA in the intestine directly affects
barrier permeability. Butyrate, for example, has been shown
to protect Caco-2 cell monolayers from Campylobacter jejuni
invasion and translocation in a concentration-dependent
manner by increasing transepithelial electrical resistance
(TEER) [113]. Similarly, butyrate, but not a mix of butyrate,
acetate, and propionate, was shown to significantly reverse
the increases in intestinal permeability, bacterial transloca-
tion, and histological damage caused by exposure to the
chemotherapeutic agent 5-Fluorouracil in mice [114]. Unlike
the first study, by using T-84 and Caco-2 monolayers, TEER
was shown to be increased by all three individual SCFAs or by
a mix thereof [115]. The ability of butyrate to increase TEER
may relate to its capacity to increase cingulin, ZO-1, and ZO-
2 proteins and mRNA levels as shown in Rat-1 fibroblasts
[116]. In the same study, butyrate was shown to increase
protein levels of cingulin in COS-7 cells and both cingulin
and occludin in HeLa cells [116]. These findings suggest that
SCFA strengthen the barrier through increase of both TEER
and TJ protein production.
The intracellular signaling events induced in IECs by
SCFA, presumably by binding to their cognitive G-protein
coupled receptors 41 and 43 (GPR41 and GPR43, resp.)
[117] and their role in barrier function, remain elusive
[118, 119]. For example, the protective effects of butyrate
against chemical-induced damage and microbial transloca-
tion were recently shown to be associated with decreased
I𝜅B phosphorylation (and presumably NF-𝜅B activity) [120],
with the latter having been shown to play both positive
and negative roles in maintenance of intestinal homeostasis
[121]. Specifically, using a T84 human colon cell model
of barrier function, butyrate was shown to protect against
dinitrophenol-induced mitochondrial damage and increased
permeability, as well as E. coli translocation. A more recent
report has shown that butyrate activates the cyclic adenosine
monophosphate (cAMP) → protein kinase A (PKA) →
cAMP responsive element binding protein (CREB) pathway
in Caco-2 cells [122]. However, butyrate had no effect on
adenylyl cyclase or phosphodiesterase, enzymes that regulate
production and degradation of cAMP, respectively. This
observation is important because these enzymes are regulated
by GPR signaling [123], suggesting that activation of the
cAMP pathway by butyrate is independent of GPR41/43
signaling. As such the roles of GPR41 and GPR43 in SCFA
signaling remain in question, though we are slowly gaining a
better understanding of the mechanisms mediated by these
formerly orphan receptors.
Besides investigation of the molecular pathways involved
in SCFA signaling, identification of bacteria and groups of
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bacteria producing SCFA, as well as the dietary component
influencing them, has gained attention.
The characterization of the complex microbial ecological
system present in the intestine using ribosomal 16S sequenc-
ing techniques has revealed that the human microbiome is
dominated by two phyla, the Firmicutes (∼75%) and Bac-
teroidetes (∼20%), with lesser contributions from Proteobac-
teria and Actinobacteria [124–126]. The Firmicutes found in
the mucosal tissues are primarily composed of Clostridium
XIVa and IV groups, which are active producers of SCFA.
It is interesting to note that levels of acetic, butyric, and
propionic acids decreased in fecal samples of IBD patients
compared to normal healthy controls [127, 128]. Similarly,
a number of reports showed that Clostridium XIVa and IV
groups decreased in patients with Crohn’s disease [129, 130].
These observations suggest that environmental conditions
(diet, inflammation, ect.) could shape microbial status and
influence their ability to produce SCFA. In addition, different
pH levels are found throughout the colon and the fermen-
tation of dietary fiber that produces SCFA is thought to be
responsible for the low pH found in the proximal colon
[131]. A recent study found that the majority of Bacteroides
and Proteobacteria species were growth-inhibited at a pH
of 5.5, a level representative of the proximal colon pH. In
contrast, the majority of Gram-positive, both Actinomycetes
and Firmicutes species, were tolerant to the lower pH. The
latter is important as the Firmicutes clusters studied included
butyrate-producing bacteria of the class Clostridia such as
Eubacterium rectale and Roseburia inulinivorans. Moreover,
using human faecal samples, it was shown that keeping fer-
mentation chambers at different pH resulted in strikingly dif-
ferent bacterial profiles. While at pH 5.5 the majority of bac-
teria detected were Firmicutes, mainly Clostridia species, at a
pH of 6.5 the majority of bacteria detected were Bacteroides
species. Therefore, pH levels may shape the gut microbial
communities by allowing growth of low pH-tolerant bacteria
such as butyrate-producing Firmicutes species [132].
The ability of diet to modify the gut microbiota and SCFA
production was also recently studied using obese patients
given three diets comprised of successively lower carbohy-
drate levels, a source for bacterial SCFA production. These
diets were administered for four weeks successively, and at
the end of each 4-week feeding period stool was collected.
The study showed that by lowering carbohydrate levels, also
representative of high protein/low carbohydrate weight loss
diets, total SCFA production was significantly and concomi-
tantly reduced, with a notably disproportionate reduction
in butyrate levels. And while the gut microbiota was not
significantly altered in terms of Firmicutes versus Bacteroides
ratio, a significant reduction in butyrate-producingRoseburia
species and Eubacterium rectale was found to correlate
with decreasing carbohydrate consumption [133]. The gut
microbiome of children in Europe (EU) who consume
mostly Western diets and that of children in rural Africa,
specifically Burkina Faso (BF), whose diet is rich in fiber,
were recently compared. BF children not only had higher
levels of Firmicutes species but also of Bacteroides species
in the genera Prevotella and Xylanibacter, with the latter
producing enzymes that can hydrolyze cellulose and xylan,
which the human enzymatic repertoire lacks. These latter
species were completely absent in the EU children, and as
predicted children in BF had higher SCFA levels than their
European counterparts [134].
Fermentation itself, which results in SCFA production,
has become a point of interest and recently two groups have
studied the metabolites formed from the fermentation of
human fecal samples in continuous 3 vessel spill-over systems
which simulate the proximal, transverse, and distal colons of
human [135].The first group utilized a large amalgamation of
fibers as the source for metabolite production and was able
to show that when more fiber was introduced into the system
at 3-fold that of baseline, an increase in colonic fermentation
and concomitant increase in saccharolytic bacteria were
observed in the fecal samples [136]. The second group took a
different approach, however, opting instead to utilize human
fecal samples and exposure to four different naturally high
fiber-containing flours.While all flours had significant effects
on resulting changes to the metabolite profile, each resulted
in distinct responses from the samples. The “Pulses” flour
(50 : 50 lentils and chickpeas) had the most promiscuous
effect on the metabolites measured, showing increases in
acetate, propionate, and tyrosine levels but decreases in
butyrate, isovalerate, and trimethylamine levels. In contrast,
the least effective flour, whole grain rye, only produced a sig-
nificant decrease in the metabolite methanol, demonstrating
how differently distinct fiber sources can act on shaping the
SCFA and metabolite profiles [137]. Further studies will be
needed to identify what fiber sources are optimal for SCFA
production and associated beneficial effects.
5. Milk, Bacterium, and the Gut
Epithelial Barrier
While identification of bacteria that provide benefit to the gut
has been the subject of intense research focus, the role the
diet has on promoting or inhibiting growth of detrimental
or pathogenic bacteria has also become a burgeoning field.
Although consumption of fermented milk has historically
been associated with beneficial effects [68], as discussed
above, it is clear that milk itself can have different effects
depending on the source from which it is derived. For
example, unlike human milk, animal milk, which forms part
of the typicalWestern diet, does not contain the antimicrobial
enzymes lactoferrin and lysozyme, which are thought to help
shape the composition of the gut microbiota [138, 139]. This
proof-of-principle was shown in a recent study using goat
milk containing human lysozyme (HLZ), produced via a
transgenic goat model, as HLZ was able to cause a compo-
sitional change in the gut microbiota of pigs. Specifically,
after 17 days of being fed HLZ these young pigs contained
significantly lower populations of Firmicutes and Clostridia
species as compared to controls. In addition, though not
statistically significant, the authors observed an increase in
the Proteobacteria population [140]. This last finding is very
interesting when taking into account a more recent study
showing that consumption of animal-derived milk fat is able
to alter the composition of gut microbiota communities in




















Figure 1: Intestinal epithelial responses to diet and microbes. Diets containing fermentable fibers, resistant starches and the like result
in increased gut fermentation and SCFA production. A constant diet containing these elements would shift the host gut microbiome to
increase the proportion of SCFA-producing bacteria. In turn, increase in SCFA production would also increase protection of the epithelium
through strengthening the barrier as mediated by increased TJ protein production and TEER, as well as decreased permeability and bacterial
translocation. Similarly, a diet containing probiotic bacteria would in time increase barrier function and integrity. Conversely, diet that
promotes the increase in populations of pathogenic or opportunistic bacteria (as with intake of milk fat) within the landscape would have
the opposite effects, decreasing TJ protein production and altering their distribution, as well as decreasing TEER and thereby compromising
barrier integrity.This would then result in increased barrier permeability resulting in increased bacterial translocation and thereby increasing
pathology such as increased intestinal inflammation.
wild-type and 𝐼𝑙10−/−mice, a genetically susceptiblemodel of
colitis. Milk fat was able to induce a bloom in the population
of Deltaproteobacteria within the 𝐼𝑙10−/− mice, specifically
they were able to show a bloom of Bilophila wadsworthia,
which coincided with an increase in taurine-conjugated bile
acids in these mice. As bile acids are a source of energy for B.
wadsworthia, it was then shown that gavage using bile acids in
lieu of milk induced the same Deltaproteobacteria bloom. A
bloom of B. wadsworthia by use of either agent also caused
a significant increase in the incidence of colitis within the
𝐼𝑙10
−/− mice [1]. Interestingly, increase in Proteobacteria is
associated with IBD in humans [141, 142]. Further studies
would be necessary before establishing cause/effect relation-
ship betweenmilk fat consumption, Proteobacteria, and IBD.
In contrast to the detrimental effects that milk fat has in
mice genetically susceptible to colitis, it has also been shown
that fermented milk in turn can have beneficial effects on
colitis models. For example, using a𝑇-𝑏𝑒𝑡−/−/𝑅𝑎𝑔2−/−model
of UC, it was recently shown that administration of B. ani-
malis subspecies lactis-containing fermented milk product
(FM) was able to significantly reduce intestinal inflammation
[143]. Amelioration of colitis was characterized by an increase
in the population of lactate-consuming butyrate-producing
bacteria species, as well as an increased presence of other
SCFAs. Furthermore, the increase in lactate-consuming bac-
terial species correlated with a significantly reduced cecal
pH. While this may seem inconsequential, low pH has been
shown to create an inhospitable environment for Enterobac-
teriaceae species to grow, with the latter having been recently
reported to be colitogenic in 𝑇-𝑏𝑒𝑡−/−/𝑅𝑎𝑔2−/− mice [144].
Further support for the beneficial effects of B. animalis subsp.
lactiswas shown in another recent study that used a ratmodel
of stress and hypersensitivity. FM containingB. lactiswas able
to reduce visceral hypersensitivity and stress-induced blood
endotoxin levels; additionally FM was able to reverse stress-
induced downregulation of TJ proteins JAM-A and occludin.
Though interesting, the contribution of B. lactis to this effect
is questionable given that the authors used FM containing
not only B. lactis but also Lactococcus lactis CNCM I-1631,
Lactobacillus bulgaricus, and Streptococcus thermophiles [71].
These studies represent an interesting point, showing how
a seemingly innocuous food product such as milk can have
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far reaching consequences on an individual’s gut microbiota.
While the direct effects on barrier function were not inves-
tigated in these studies, the use of colitis models provides at
least a reference point for potential beneficial effects and will
help define molecular mechanisms of action.
Though the gut barrier landscape is a very complex
environment, taken together, we can now envision it as one
in which intake of diet affects the gut in one of two ways.
On the one hand, it can affect the gut by promoting the
increase of pathogenic or opportunistic bacteria and thereby
damaging the barrier through increases in permeability and
bacterial translocation, along with decreases in TJ proteins
and TEER resulting in pathology such as inflammation. On
the other hand, a diet that includes probiotic bacterial species
or prebiotic fibers that result in SCFA would strengthen the
epithelial barrier by increasing TJ proteins and TEER, as
well as decreasing permeability and bacterial translocation
helping to avoid or ameliorate pathology (Figure 1).
6. Perspective
The impact of bacteria on intestinal barrier function is
clearly illustrated by the action of specific pathogenic enteric
bacteria that have evolved remarkable means to penetrate
and circumvent this important host defense mechanism.
Pathogenic enteric bacteria such as Salmonella, Shigella, and
Yersinia species, utilized specific effector proteins to alter
intestinal tight junction proteins and weaken barrier func-
tion. On the other hand, millions of years of evolution have
led to the acquisition of a complex intestinal microbiota
that was selected for its capacity to maintain a symbiotic
relationship with the host. This biota has formed through
a complex set of environmental factors including dietary
habits. Evidence suggests that this biota not only prevents
pathogenic bacteria from accessing the epithelial barrier, but
also actively promotes the state of a healthy barrier through
the action of their metabolism.
Some bacteria such as Lactobacillus plantarum appear to
modulate the epithelial barrier through the action of secreted
protein (LGG p40) whereas other such as Clostridium likely
influence the barrier through production of metabolites
(SCFA). In view of the richness and diversity of the micro-
biota, it would be important to “mine” this biota and identify
microorganisms with “barrier protective function.” Because
of the interplay between diet and microbial composition,
identification of nutritional components that contribute to
barrier function should also be a forefront priority. Integra-
tion ofmicrobial genomic,metabolomics, and transcriptomic
technology would be essential to carry this mission forward.
Understanding the intricate relationship between epithelial
barrier, microbe, and diet would undeniably contribute key
knowledge that could be harness for therapeutic purpose.
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[42] L. González-Mariscal, R. Tapia, and D. Chamorro, “Crosstalk of
tight junction components with signaling pathways,” Biochim-
ica et Biophysica Acta, vol. 1778, no. 3, pp. 729–756, 2008.
[43] V. Dodane and B. Kachar, “Identification of isoforms of G
proteins and PKC that colocalize with tight junctions,” Journal
of Membrane Biology, vol. 149, no. 3, pp. 199–209, 1996.
[44] R. O. Stuart and S. K. Nigam, “Regulated assembly of tight
junctions by protein kinase C,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 92, no.
13, pp. 6072–6076, 1995.
[45] T. Suzuki, B. C. Elias, A. Seth et al., “PKC𝜂 regulates occludin
phosphorylation and epithelial tight junction integrity,” Pro-
ceedings of the National Academy of Sciences of the United States
of America, vol. 106, no. 1, pp. 61–66, 2009.
[46] C. G. Günther, H. Neumann, M. F. Neurath, and C. Becker,
“Apoptosis, necrosis and necroptosis: cell death regulation inthe
intestinal epithelium,” Gut, 2012.
[47] G. T. Eisenhoffer, P. D. Loftus, M. Yoshigi et al., “Crowding
induces live cell extrusion to maintain homeostatic cell num-
bers in epithelia,” Nature, vol. 484, no. 7395, pp. 546–549, 2012.
[48] P. A. Hall, P. J. Coates, B. Ansari, and D. Hopwood, “Regulation
of cell number in the mammalian gastrointestinal tract: the
importance of apoptosis,” Journal of Cell Science, vol. 107, part
12, pp. 3569–3577, 1994.
BioMed Research International 9
[49] M. Krajewska, H. G. Wang, S. Krajewski et al., “Immunohis-
tochemical analysis of in vivo patterns of expression of CPP32
(Caspase-3), a cell death protease,” Cancer Research, vol. 57, no.
8, pp. 1605–1613, 1997.
[50] T. F. Bullen, S. Forrest, F. Campbell et al., “Characterization of
epithelial cell shedding fromhuman small intestine,” Laboratory
Investigation, vol. 86, no. 10, pp. 1052–1063, 2006.
[51] A. M. Marchiando, L. Shen, W. V. Graham et al., “The epithelial
barrier is maintained by in vivo tight junction expansion during
pathologic intestinal epithelial shedding,”Gastroenterology, vol.
140, no. 4, pp. 1208.e2–1218.e2, 2011.
[52] C. Günther, E. Martini, N. Wittkopf et al., “Caspase-8 regulates
TNF-𝛼-induced epithelial necroptosis and terminal ileitis,”
Nature, vol. 477, no. 7364, pp. 335–339, 2011.
[53] A. J. M. Watson, “Necrosis and apoptosis in the gastrointestinal
tract,” Gut, vol. 37, no. 2, pp. 165–167, 1995.
[54] S. Y. Proskuryakov, A. G. Konoplyannikov, and V. L. Gabai,
“Necrosis: a specific form of programmed cell death?” Exper-
imental Cell Research, vol. 283, no. 1, pp. 1–16, 2003.
[55] P. S. Welz, A. Wullaert, K. Vlantis et al., “FADD prevents
RIP3-mediated epithelial cell necrosis and chronic intestinal
inflammation,” Nature, vol. 477, no. 7364, pp. 330–334, 2011.
[56] R. Moriez, C. Salvador-Cartier, V.Theodorou, J. Fioramonti, H.
Eutamene, and L. Bueno, “Myosin light chain kinase is involved
in lipopolysaccharide-induced disruption of colonic epithelial
barrier and bacterial translocation in rats,” American Journal of
Pathology, vol. 167, no. 4, pp. 1071–1079, 2005.
[57] L. L. Wu, H. D. Chiu, W. H. Peng et al., “Epithelial inducible
nitric oxide synthase causes bacterial translocation by impair-
ment of enterocytic tight junctions via intracellular signals of
Rho-associated kinase and protein kinase C zeta,” Critical Care
Medicine, vol. 39, no. 9, pp. 2087–2098, 2011.
[58] K. L. Madsen, “Interactions between microbes and the gut epi-
thelium,” Journal of Clinical Gastroenterology, supplement 45,
pp. S111–S114, 2011.
[59] I. Jarchum, M. Liu, L. Lipuma, and E. G. Pamer, “Toll-like
receptor 5 stimulation protects mice from acute Clostridium
difficile colitis,” Infection and Immunity, vol. 79, no. 4, pp. 1498–
1503, 2011.
[60] E. Cario, G. Gerken, and D. K. Podolsky, “Toll-like receptor 2
controls mucosal inflammation by regulating epithelial barrier
function,” Gastroenterology, vol. 132, no. 4, pp. 1359–1374, 2007.
[61] D. Rachmilewitz, K. Katakura, F. Karmeli et al., “Toll-like recep-
tor 9 signaling mediates the anti-inflammatory effects of probi-
otics in murine experimental colitis,”Gastroenterology, vol. 126,
no. 2, pp. 520–528, 2004.
[62] E. Cario, G. Gerken, and D. K. Podolsky, “Toll-like receptor 2
enhances ZO-1-associated intestinal epithelial barrier integrity
via protein kinase C,” Gastroenterology, vol. 127, no. 1, pp. 224–
238, 2004.
[63] M. Fukata, K. S. Michelsen, R. Eri et al., “Toll-like receptor-4 is
required for intestinal response to epithelial injury and limiting
bacterial translocation in a murine model of acute colitis,”
American Journal of Physiology, vol. 288, no. 5, pp. G1055–
G1065, 2005.
[64] A. Nenci, C. Becker, A. Wullaert et al., “Epithelial NEMO links
innate immunity to chronic intestinal inflammation,” Nature,
vol. 446, no. 7135, pp. 557–561, 2007.
[65] M. Pasparakis, “Regulation of tissue homeostasis by NF-B
signalling: implications for inflammatory diseases,” Nature
Reviews Immunology, vol. 9, no. 11, pp. 778–788, 2009.
[66] R. Kajino-Sakamoto, M. Inagaki, E. Lippert et al., “Enterocyte-
derived TAK1 signaling prevents epithelium apoptosis and the
development of ileitis and colitis,” Journal of Immunology, vol.
181, no. 2, pp. 1143–1152, 2008.
[67] K. A. Steinbrecher, E. Harmel-Laws, R. Sitcheran, and A. S.
Baldwin, “Loss of epithelial RelA results in deregulated intesti-
nal proliferative/apoptotic homeostasis and susceptibility to
inflammation,” Journal of Immunology, vol. 180, no. 4, pp. 2588–
2599, 2008.
[68] E. Metchnikoff, Immunity in Infective Diseases, Google Books,
1905.
[69] R. Fuller, “Probiotics in human medicine,” Gut, vol. 32, no. 4,
pp. 439–442, 1991.
[70] R. K.Duary,M.A. Bhausaheb, V. K. Batish, and S. Grover, “Anti-
inflammatory and immunomodulatory efficacy of indigenous
probiotic Lactobacillus plantarum Lp91 in colitis mouse model,”
Molecular Biology Reports, vol. 39, no. 4, pp. 4765–4775, 2012.
[71] S. Agostini, M. Goubern, V. Tondereau et al., “A marketed fer-
mented dairy product containing Bifidobacterium lactisCNCM
I-2494 suppresses gut hypersensitivity and colonic barrier dis-
ruption induced by acute stress in rats,” Neurogastroenterology
and Motility, vol. 24, no. 4, pp. 376–e172, 2012.
[72] N. Ueno, M. Fujiya, S. Segawa et al., “Heat-killed body of
lactobacillus brevis SBC8803 ameliorates intestinal injury in
a murine model of colitis by enhancing the intestinal barrier
function,” Inflammatory Bowel Disease, vol. 17, no. 11, pp. 2235–
2250, 2011.
[73] F. Yan, H. Cao, T. L. Cover et al., “Colon-specific delivery of a
probiotic-derived soluble protein ameliorates intestinal inflam-
mation in mice through an EGFR-dependent mechanism,”
Journal of Clinical Investigation, vol. 121, no. 6, pp. 2242–2253,
2011.
[74] M. Roselli, A. Finamore, S. Nuccitelli et al., “Prevention of
TNBS-induced colitis by different Lactobacillus and Bifidobac-
terium strains is associated with an expansion of 𝛾𝛿T and
regulatory T cells of intestinal intraepithelial lymphocytes,”
Inflammatory BowelDiseases, vol. 15, no. 10, pp. 1526–1536, 2009.
[75] O. Kanauchi, M. Fukuda, Y. Matsumoto et al., “Eubacterium
limosum ameliorates experimental colitis and metabolite of
microbe attenuates colonic inflammatory action with increase
of mucosal integrity,”World Journal of Gastroenterology, vol. 12,
no. 7, pp. 1071–1077, 2006.
[76] Y. Wang, Y. Liu, A. Sidhu, Z. Ma, C. McClain, and W. Feng,
“Lactobacillus rhamnosus GG culture supernatant ameliorates
acute alcohol-induced intestinal permeability and liver injury,”
American Journal of Physiology, vol. 303, no. 1, pp. G32–G41,
2012.
[77] I. Russo, A. Luciani, P. De Cicco, E. Troncone, and C. Ciacci,
“Butyrate attenuates lipopolysaccharide-induced inflammation
in intestinal cells and Crohn’s mucosa through modulation of
antioxidant defense machinery,” PLoS ONE, vol. 7, no. 3, Article
ID e32841, 2012.
[78] Y. Wang, I. Kirpich, Y. Liu et al., “Lactobacillus rhamnosus
GG treatment potentiates intestinal hypoxia-inducible factor,
promotes intestinal integrity and ameliorates alcohol-induced
liver injury,” The American Journal of Pathology, vol. 179, no. 6,
pp. 2866–2875, 2011.
[79] H. Qin, Z. Zhang, X. Hang, and Y. Jiang, “L. plantarum prevents
Enteroinvasive Escherichia coli-induced tight junction proteins
changes in intestinal epithelial cells,” BMC Microbiology, vol. 9,
article 63, 2009.
10 BioMed Research International
[80] A. A. Zyrek, C. Cichon, S. Helms, C. Enders, U. Sonnenborn,
and M. A. Schmidt, “Molecular mechanisms underlying the
probiotic effects of Escherichia coliNissle 1917 involve ZO-2 and
PKC𝜁 redistribution resulting in tight junction and epithelial
barrier repair,” Cellular Microbiology, vol. 9, no. 3, pp. 804–816,
2007.
[81] K. Madsen, A. Cornish, P. Soper et al., “Probiotic bacteria
enhance murine and human intestinal epithelial barrier func-
tion,” Gastroenterology, vol. 121, no. 3, pp. 580–591, 2001.
[82] C. Pagnini, R. Saeed, G. Bamias, K. O. Arseneau, T. T. Pizarro,
and F. Cominelli, “Probiotics promote gut health through
stimulation of epithelial innate immunity,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 107, no. 1, pp. 454–459, 2010.
[83] C. Ahn and M. E. Stiles, “Antibacterial activity of lactic acid
bacteria isolated from vacuum-packaged meats,” Journal of
Applied Bacteriology, vol. 69, no. 3, pp. 302–310, 1990.
[84] T. Pessi, Y. Sütas, A. Marttinen, and E. Isolauri, “Probiotics
reinforce mucosal degradation of antigens in rats: implications
for therapeutic use of probiotics,” Journal of Nutrition, vol. 128,
no. 12, pp. 2313–2318, 1998.
[85] M. Y. Lin and F. J. Chang, “Antioxidative effect of intestinal
bacteriaBifidobacterium longumATCC 15708 and Lactobacillus
acidophilus ATCC 4356,” Digestive Diseases and Sciences, vol.
45, no. 8, pp. 1617–1622, 2000.
[86] T. Okamoto, M. Sasaki, T. Tsujikawa, Y. Fujiyama, T. Bamba,
and M. Kusunoki, “Preventive efficacy of butyrate enemas and
oral administration of Clostridium butyricum M588 in dextran
sodium sulfate-induced colitis in rats,” Journal of Gastroenterol-
ogy, vol. 35, no. 5, pp. 341–346, 2000.
[87] H. F.Wang, C. Y. Tseng,M. H. Chang et al., “Anti-inflammatory
effects of probiotic Lactobacillus paracasi on ventricles of
BALB/C mice treated with ovalbumin,” The Chinese Journal of
Physiology, vol. 55, no. 1, pp. 37–46, 2012.
[88] M. H. Land, K. Rouster-Stevens, C. R. Woods, M. L. Cannon,
J. Cnota, and A. K. Shetty, “Lactobacillus sepsis associated with
probiotic therapy,” Pediatrics, vol. 115, no. 1, pp. 178–181, 2005.
[89] E. Apostolou, P. V. Kirjavainen, M. Saxelin et al., “Good adhe-
sion properties of probiotics: a potential risk for bacteremia?”
FEMS Immunology and Medical Microbiology, vol. 31, no. 1, pp.
35–39, 2001.
[90] J. Oyake, M. Otaka, T. Matsuhashi et al., “Over-expression of
70-kDa heat shock protein confers protection against
monochloramine-induced gastric mucosal cell injury,” Life
Sciences, vol. 79, no. 3, pp. 300–305, 2006.
[91] J. J. Malago, J. F. J. G. Koninkx, P. C. J. Tooten, E. A. van Liere,
and J. E. van Dijk, “Anti-inflammatory properties of heat shock
protein 70 and butyrate on Salmonella-induced interleukin-8
secretion in enterocyte-like Caco-2 cells,” Clinical and Experi-
mental Immunology, vol. 141, no. 1, pp. 62–71, 2005.
[92] D. L. Arvans, S. R. Vavricka, H. Ren et al., “Luminal bacterial
flora determines physiological expression of intestinal epithelial
cytoprotective heat shock proteins 25 and 72,”American Journal
of Physiology, vol. 288, no. 4, pp. G696–G704, 2005.
[93] M. L. Johansson, G. Molin, B. Jeppsson, S. Nobaek, S. Ahrne,
and S. Bengmark, “Administration of different Lactobacillus
strains in fermented oatmeal soup: in vivo colonization of
human intestinal mucosa and effect on the indigenous flora,”
Applied and Environmental Microbiology, vol. 59, no. 1, pp. 15–
20, 1993.
[94] P.Mangell, P. Nejdfors,M.Wang et al., “Lactobacillus plantarum
299 v inhibits Escherichia coli-induced intestinal permeability,”
Digestive Diseases and Sciences, vol. 47, no. 3, pp. 511–516, 2002.
[95] M. Schultz, C. Veltkamp, L. A. Dieleman et al., “Lactobacillus
plantarum 299 v in the treatment and prevention of sponta-
neous colitis in interleukin-10-deficient mice,” Inflammatory
Bowel Diseases, vol. 8, no. 2, pp. 71–80, 2002.
[96] K. Niedzielin, H. Kordecki, and B. Birkenfeld, “A controlled,
double-blind, randomized study on the efficacy of Lactobacillus
plantarum 299 v in patients with irritable bowel syndrome,”
European Journal of Gastroenterology and Hepatology, vol. 13,
no. 10, pp. 1143–1147, 2001.
[97] M.Wullt, M. L. J. Hagslätt, and I. Odenholt, “Lactobacillus plan-
tarum 299 v for the treatment of recurrent Clostridium difficile-
associated diarrhoea: a double-blind, placebo-controlled trial,”
Scandinavian Journal of Infectious Diseases, vol. 35, no. 6-7, pp.
365–367, 2003.
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